SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-003610
Filing Date
2022-03-15
Accepted
2022-03-15 07:07:21
Documents
14
Period of Report
2022-03-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20220315x8k.htm   iXBRL 8-K 45398
2 EX-99.1 alt-20220315xex99d1.htm EX-99.1 188564
3 GRAPHIC alt-20220315xex99d1002.jpg GRAPHIC 8709
  Complete submission text file 0001558370-22-003610.txt   382118

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20220315.xsd EX-101.SCH 3049
5 EX-101.LAB alt-20220315_lab.xml EX-101.LAB 15906
6 EX-101.PRE alt-20220315_pre.xml EX-101.PRE 10119
8 EXTRACTED XBRL INSTANCE DOCUMENT alt-20220315x8k_htm.xml XML 4868
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

IRS No.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 22739090
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences